Is Neurocrine Biosciences Stock a Good Investment?
Neurocrine Biosciences Investment Advice | NBIX |
- Examine Neurocrine Biosciences' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Neurocrine Biosciences' leadership team and their track record. Good management can help Neurocrine Biosciences navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Neurocrine Biosciences' business and its evolving consumer preferences.
- Compare Neurocrine Biosciences' performance and market position to its competitors. Analyze how Neurocrine Biosciences is positioned in terms of product offerings, innovation, and market share.
- Check if Neurocrine Biosciences pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Neurocrine Biosciences' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Neurocrine Biosciences stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Neurocrine Biosciences is a good investment.
Sell | Buy |
Hold
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | Very Low | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Strong | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Neurocrine Biosciences Stock
Researching Neurocrine Biosciences' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 95.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 0.44. Neurocrine Biosciences last dividend was issued on the 29th of December 1995.
To determine if Neurocrine Biosciences is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Neurocrine Biosciences' research are outlined below:
| Neurocrine Biosciences generated a negative expected return over the last 90 days | |
| Neurocrine Biosciences has a strong financial position based on the latest SEC filings | |
| Over 95.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: UPDATE 1-Neurocrine Biosciences Huntingtons disease drug gets FDA approval |
Neurocrine Biosciences uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Neurocrine Biosciences. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Neurocrine Biosciences' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 7th of February 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 7th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Neurocrine Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Neurocrine Biosciences' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2010-10-28 | 2010-09-30 | 0.05 | 0.06 | 0.01 | 20 | ||
1997-10-31 | 1997-09-30 | 0.05 | 0.06 | 0.01 | 20 | ||
2014-04-30 | 2014-03-31 | -0.19 | -0.17 | 0.02 | 10 | ||
2012-07-31 | 2012-06-30 | -0.03 | -0.01 | 0.02 | 66 | ||
2011-07-28 | 2011-06-30 | 0.06 | 0.04 | -0.02 | 33 | ||
2013-10-29 | 2013-09-30 | -0.2 | -0.17 | 0.03 | 15 | ||
1998-11-02 | 1998-09-30 | -0.19 | -0.22 | -0.03 | 15 | ||
1998-08-04 | 1998-06-30 | -0.17 | -0.14 | 0.03 | 17 |
Know Neurocrine Biosciences' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Neurocrine Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Neurocrine Biosciences backward and forwards among themselves. Neurocrine Biosciences' institutional investor refers to the entity that pools money to purchase Neurocrine Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Goldman Sachs Group Inc | 2023-12-31 | 1.4 M | Dodge & Cox | 2023-12-31 | 1.3 M | Dsm Capital Partners Llc | 2023-12-31 | 1.2 M | Pictet Asset Manangement Sa | 2023-12-31 | 1.2 M | Deerfield Management Co | 2023-09-30 | 1.2 M | Wellington Management Company Llp | 2023-12-31 | 1.2 M | Rock Springs Capital Management Lp | 2023-12-31 | 1.2 M | Brown Advisory Holdings Inc | 2023-12-31 | 1.1 M | Armistice Capital, Llc | 2023-12-31 | 1 M | Blackrock Inc | 2023-12-31 | 13.6 M | Vanguard Group Inc | 2023-12-31 | 9.7 M |
Neurocrine Biosciences' market capitalization trends
The company currently falls under 'Large-Cap' category with a current market capitalization of 13.97 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Neurocrine Biosciences's market, we take the total number of its shares issued and multiply it by Neurocrine Biosciences's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Market Cap |
|
Neurocrine Biosciences' profitablity analysis
Neurocrine Biosciences' profitability indicators refer to fundamental financial ratios that showcase Neurocrine Biosciences' ability to generate income relative to its revenue or operating costs. If, let's say, Neurocrine Biosciences is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Neurocrine Biosciences' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Neurocrine Biosciences' profitability requires more research than a typical breakdown of Neurocrine Biosciences' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.08 | 0.08 | |
| Return On Capital Employed | 0.1 | 0.10 | |
| Return On Assets | 0.08 | 0.08 | |
| Return On Equity | 0.11 | 0.12 |
Determining Neurocrine Biosciences' profitability involves analyzing its financial statements and using various financial metrics to determine if Neurocrine Biosciences is a good buy. For example, gross profit margin measures Neurocrine Biosciences' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Neurocrine Biosciences' profitability and make more informed investment decisions.
The data published in Neurocrine Biosciences' official financial statements usually reflect Neurocrine Biosciences' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Neurocrine Biosciences. For example, before you start analyzing numbers published by Neurocrine accountants, it's critical to develop an understanding of what Neurocrine Biosciences' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Neurocrine Biosciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Neurocrine Biosciences' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Neurocrine Biosciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Neurocrine Biosciences. Please utilize our Beneish M Score to check the likelihood of Neurocrine Biosciences' management manipulating its earnings.
Evaluate Neurocrine Biosciences' management efficiency
Neurocrine Biosciences has return on total asset (ROA) of 0.0878 % which means that it generated a profit of $0.0878 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1268 %, meaning that it created $0.1268 on every $100 dollars invested by stockholders. Neurocrine Biosciences' management efficiency ratios could be used to measure how well Neurocrine Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.08 in 2024. Return On Capital Employed is likely to rise to 0.10 in 2024. At this time, Neurocrine Biosciences' Asset Turnover is fairly stable compared to the past year.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 22.85 | 23.99 | |
| Net Current Asset Value | 0.00 | 0.00 | |
| Tangible Asset Value | 0.00 | 0.00 | |
| Tangible Book Value Per Share | 22.42 | 23.54 | |
| Enterprise Value Over EBITDA | 31.36 | 32.93 | |
| Price Book Value Ratio | 5.77 | 6.13 | |
| Enterprise Value Multiple | 31.36 | 32.93 | |
| Price Fair Value | 5.77 | 6.13 | |
| Enterprise Value | 6.2 B | 6.6 B |
The analysis of Neurocrine Biosciences' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Neurocrine Biosciences' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Neurocrine Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta 0.277 |
Basic technical analysis of Neurocrine Stock
As of the 1st of May, Neurocrine Biosciences secures the Mean Deviation of 1.23, risk adjusted performance of (0.01), and Standard Deviation of 1.62. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Neurocrine Biosciences, as well as the relationship between them. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of past prices, or the prices will eventually revert. We were able to collect and analyze data for thirteen technical drivers for Neurocrine Biosciences, which can be compared to its peers in the industry. Please verify Neurocrine Biosciences market risk adjusted performance and treynor ratio to decide if Neurocrine Biosciences is priced some-what accurately, providing market reflects its recent price of 137.54 per share. Given that Neurocrine Biosciences has information ratio of (0.06), we recommend you to check Neurocrine Biosciences's last-minute market performance to make sure the company can sustain itself at a future point.Neurocrine Biosciences' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Neurocrine Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Neurocrine Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Neurocrine Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Richard Pops few days ago Acquisition by Richard Pops of 1700 shares of Neurocrine Biosciences at 42.76 subject to Rule 16b-3 | ||
George Morrow over a month ago Disposition of 20000 shares by George Morrow of Neurocrine Biosciences at .79 subject to Rule 16b-3 | ||
Eiry Roberts over three months ago Sale by Eiry Roberts of 6978 shares of Neurocrine Biosciences | ||
Stephen Sherwin over three months ago Bona fide gift to Stephen Sherwin of 2750 shares of Neurocrine Biosciences subject to Section 16 | ||
Eiry Roberts over six months ago Sale by Eiry Roberts of 3198 shares of Neurocrine Biosciences | ||
Stephen Sherwin over six months ago Exercise or conversion by Stephen Sherwin of 12000 shares of Neurocrine Biosciences subject to Rule 16b-3 | ||
Vale Wylie W over a year ago Disposition of 12000 shares by Vale Wylie W of Neurocrine Biosciences subject to Rule 16b-3 | ||
Eiry Roberts over a year ago Sale by Eiry Roberts of 1457 shares of Neurocrine Biosciences |
Understand Neurocrine Biosciences' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Neurocrine Biosciences' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.01) | |||
| Market Risk Adjusted Performance | (0.08) | |||
| Mean Deviation | 1.23 | |||
| Coefficient Of Variation | (4,380) | |||
| Standard Deviation | 1.62 | |||
| Variance | 2.63 | |||
| Information Ratio | (0.06) | |||
| Jensen Alpha | (0.07) | |||
| Total Risk Alpha | (0.17) | |||
| Treynor Ratio | (0.09) | |||
| Maximum Drawdown | 6.58 | |||
| Value At Risk | (2.36) | |||
| Potential Upside | 2.61 | |||
| Skewness | 0.2163 | |||
| Kurtosis | 0.8521 |
| Risk Adjusted Performance | (0.01) | |||
| Market Risk Adjusted Performance | (0.08) | |||
| Mean Deviation | 1.23 | |||
| Coefficient Of Variation | (4,380) | |||
| Standard Deviation | 1.62 | |||
| Variance | 2.63 | |||
| Information Ratio | (0.06) | |||
| Jensen Alpha | (0.07) | |||
| Total Risk Alpha | (0.17) | |||
| Treynor Ratio | (0.09) | |||
| Maximum Drawdown | 6.58 | |||
| Value At Risk | (2.36) | |||
| Potential Upside | 2.61 | |||
| Skewness | 0.2163 | |||
| Kurtosis | 0.8521 |
Consider Neurocrine Biosciences' intraday indicators
Neurocrine Biosciences intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Neurocrine Biosciences stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 21536.64 | |||
| Daily Balance Of Power | (0.43) | |||
| Rate Of Daily Change | 0.99 | |||
| Day Median Price | 138.91 | |||
| Day Typical Price | 138.45 | |||
| Price Action Indicator | (2.04) | |||
| Period Momentum Indicator | (1.35) | |||
| Relative Strength Index | 39.97 |
Neurocrine Biosciences Corporate Filings
F4 | 17th of April 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 10th of April 2024 Other Reports | ViewVerify | |
10K | 9th of February 2024 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
8K | 7th of February 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Neurocrine Stock media impact
Far too much social signal, news, headlines, and media speculation about Neurocrine Biosciences that are available to investors today. That information is available publicly through Neurocrine media outlets and privately through word of mouth or via Neurocrine internal channels. However, regardless of the origin, that massive amount of Neurocrine data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Neurocrine Biosciences news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Neurocrine Biosciences relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Neurocrine Biosciences' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Neurocrine Biosciences alpha.
Neurocrine Biosciences Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Neurocrine Biosciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Neurocrine Biosciences Historical Investor Sentiment
Investor biases related to Neurocrine Biosciences' public news can be used to forecast risks associated with an investment in Neurocrine. The trend in average sentiment can be used to explain how an investor holding Neurocrine can time the market purely based on public headlines and social activities around Neurocrine Biosciences. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Neurocrine Biosciences' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Neurocrine Biosciences and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Neurocrine Biosciences news discussions. The higher the estimate score, the more favorable the investor's outlook on Neurocrine Biosciences.
Neurocrine Biosciences Maximum Pain Price across 2024-05-17 Option Contracts
Neurocrine Biosciences' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Neurocrine Biosciences close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Neurocrine Biosciences' options.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Neurocrine Biosciences without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Balance Of Power Now
Balance Of PowerCheck stock momentum by analyzing Balance Of Power indicator and other technical ratios |
| All Next | Launch Module |
Neurocrine Biosciences Corporate Directors
Neurocrine Biosciences corporate directors refer to members of a Neurocrine Biosciences board of directors. The board of directors generally takes responsibility for the Neurocrine Biosciences' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Neurocrine Biosciences' board members must vote for the resolution. The Neurocrine Biosciences board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Joseph Mollica | Independent Director | Profile | |
| George Morrow | Director | Profile | |
| Richard Pops | Independent Director | Profile | |
| Alfred Sandrock | Director | Profile |
How to buy Neurocrine Stock?
To provide specific investment advice or recommendations on Neurocrine Biosciences stock, we recommend investors consider the following general factors when evaluating Neurocrine Biosciences. This will help you to make an informed decision on whether to include Neurocrine Biosciences in one of your diversified portfolios:- Examine Neurocrine Biosciences' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Neurocrine Biosciences' leadership team and their track record. Good management can help Neurocrine Biosciences navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Neurocrine Biosciences' business and its evolving consumer preferences.
- Compare Neurocrine Biosciences' performance and market position to its competitors. Analyze how Neurocrine Biosciences is positioned in terms of product offerings, innovation, and market share.
- Check if Neurocrine Biosciences pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Neurocrine Biosciences' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Neurocrine Biosciences stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Neurocrine Biosciences is a good investment.
Already Invested in Neurocrine Biosciences?
The danger of trading Neurocrine Biosciences is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Neurocrine Biosciences is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Neurocrine Biosciences. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Neurocrine Biosciences is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Neurocrine Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Neurocrine Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neurocrine Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neurocrine Biosciences Stock: Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurocrine Biosciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Neurocrine Stock please use our How to Invest in Neurocrine Biosciences guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Complementary Tools for Neurocrine Stock analysis
When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is Neurocrine Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurocrine Biosciences. If investors know Neurocrine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurocrine Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.648 | Earnings Share 2.47 | Revenue Per Share 19.315 | Quarterly Revenue Growth 0.25 | Return On Assets 0.0878 |
The market value of Neurocrine Biosciences is measured differently than its book value, which is the value of Neurocrine that is recorded on the company's balance sheet. Investors also form their own opinion of Neurocrine Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Neurocrine Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurocrine Biosciences' market value can be influenced by many factors that don't directly affect Neurocrine Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Neurocrine Biosciences' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Neurocrine Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurocrine Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.